> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Fresenius Recalls 2 Lots Dexmedetomidine
- URL: https://www.fdaweb.com/fresenius-recalls-2-lots-dexmedetomidine/
- Published: 2020-07-23T12:00:00.000Z
- Updated: 2026-09-14T16:22:15.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5147270

Fresenius Kabi has recalled two lots of dexmedetomidine HCl in 0.9% sodium chloride injection due to the possibility of a trace amount of lidocaine present in the two lots. The drug is approved for intravenous use and indicated for sedation of non-intubated patients prior to or during surgical and other procedures. To date, no adverse drug experience reports have been received for either of the lots, a [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/fresenius-kabi-issues-voluntary-nationwide-recall-two-lots-dexmedetomidine-hydrochloride-injection?utm%5Fcampaign=FDA%20MedWatch%3A%20Dexmedetomidine%20Due%20to%20Presence%20of%20Lidocaine&utm%5Fmedium=email&utm%5Fsource=Eloqua) says. “Administration of dexmedetomidine HCl containing trace amounts of lidocaine to a patient with lidocaine allergy could result in anaphylaxis, a potentially life-threatening condition,” it says.